NASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free RXST Stock Alerts $62.94 -1.35 (-2.10%) (As of 12:35 PM ET) Add Compare Share Share Today's Range$62.65▼$64.4850-Day Range$46.20▼$64.2952-Week Range$20.66▼$66.54Volume123,677 shsAverage Volume447,658 shsMarket Capitalization$2.33 billionP/E RatioN/ADividend YieldN/APrice Target$60.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get RxSight alerts: Email Address RxSight MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4.2% Downside$60.63 Price TargetShort InterestBearish5.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 10 Articles This WeekInsider TradingSelling Shares$4.49 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.78) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.93 out of 5 starsMedical Sector627th out of 929 stocksOphthalmic Goods Industry6th out of 7 stocks 2.5 Analyst's Opinion Consensus RatingRxSight has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRxSight has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about RxSight's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.02% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXST. Previous Next 2.6 News and Social Media Coverage News SentimentRxSight has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for RxSight this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for RXST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,494,600.00 in company stock.Percentage Held by Insiders21.13% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.78) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -50.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -50.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 14.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadThe AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016.Get the full story here. About RxSight Stock (NASDAQ:RXST)RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More RXST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RXST Stock News HeadlinesMay 7, 2024 | insidertrades.comRxSight, Inc. (NASDAQ:RXST) CEO Sells $2,406,000.00 in StockMay 3, 2024 | insidertrades.comInsider Selling: RxSight, Inc. (NASDAQ:RXST) CFO Sells 10,000 Shares of StockMay 13 at 7:50 PM | finance.yahoo.comRxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 13 at 4:05 PM | globenewswire.comRxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 11, 2024 | americanbankingnews.comRxSight, Inc. (NASDAQ:RXST) Receives Consensus Recommendation of "Buy" from BrokeragesMay 10, 2024 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$72.75May 9, 2024 | msn.comWhy RxSight (RXST) Shares Are FallingMay 9, 2024 | finance.yahoo.comRxSight First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | msn.comRxSight price raises equity at $56 per shareMay 9, 2024 | americanbankingnews.comRxSight (NASDAQ:RXST) PT Raised to $72.00May 9, 2024 | americanbankingnews.comNeedham & Company LLC Increases RxSight (NASDAQ:RXST) Price Target to $75.00May 9, 2024 | americanbankingnews.comRxSight (NASDAQ:RXST) PT Raised to $68.00 at Wells Fargo & CompanyMay 8, 2024 | globenewswire.comRxSight, Inc. Announces Pricing of Public Offering of Common StockMay 8, 2024 | markets.businessinsider.comRxSight’s Strong Q1 Performance and Market Expansion Justify Buy RatingMay 8, 2024 | americanbankingnews.comRxSight (NASDAQ:RXST) PT Raised to $68.00May 8, 2024 | americanbankingnews.comRxSight (NASDAQ:RXST) Shares Gap Up Following Analyst UpgradeMay 7, 2024 | markets.businessinsider.comRxSight Outperforms with Strong Q1 Results and Raised Guidance: Buy Rating AffirmedMay 7, 2024 | markets.businessinsider.comWhat 10 Analyst Ratings Have To Say About RxSightMay 7, 2024 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comRxSight Inc (RXST) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 7, 2024 | americanbankingnews.comRxSight, Inc. (NASDAQ:RXST) CEO Ronald M. Md Kurtz Sells 40,000 Shares of StockMay 6, 2024 | msn.comRXST Stock Earnings: RxSight Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | finance.yahoo.comRxSight Inc (RXST) Surpasses Analyst Revenue Forecasts in Q1 2024May 6, 2024 | globenewswire.comRxSight, Inc. Reports First Quarter 2024 Financial ResultsMay 6, 2024 | msn.comStocks Set to Open Higher as Investors Await More Corporate Earnings and Fed SpeakSee More Headlines Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/16/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Ophthalmic goods Sub-IndustryN/A Current SymbolNASDAQ:RXST CUSIPN/A CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees374Year FoundedN/APrice Target and Rating Average Stock Price Target$60.63 High Stock Price Target$75.00 Low Stock Price Target$32.00 Potential Upside/Downside-5.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-44.01% Pretax Margin-43.98% Return on Equity-27.68% Return on Assets-23.96% Debt Debt-to-Equity RatioN/A Current Ratio9.20 Quick Ratio8.18 Sales & Book Value Annual Sales$89.08 million Price / Sales26.70 Cash FlowN/A Price / Cash FlowN/A Book Value$4.43 per share Price / Book14.51Miscellaneous Outstanding Shares36,990,000Free Float29,172,000Market Cap$2.38 billion OptionableOptionable Beta1.21 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Ronald M. Kurtz M.D. (Age 61)President, CEO & Director Comp: $1.03MMs. Shelley B. Thunen (Age 70)Chief Financial Officer Comp: $651.36kDr. Ilya Goldshleger Ph.D. (Age 49)Chief Operating Officer Comp: $657.81kMr. Eric J. Weinberg (Age 63)Chief Commercial Officer Comp: $638.9kMs. Rebecca WillistonVice President of Accounting & FinanceMr. Matt Haller Ph.D.Chief Technology OfficerAlex HuangInvestor RelationsMr. Roy FreemanVice President of MarketingMs. Caroline VaughnVice President of Human ResourcesMr. Scott GainesSenior VP of Commercial Operations & Business ProcessMore ExecutivesKey CompetitorsSTAAR SurgicalNASDAQ:STAABausch Health CompaniesNYSE:BHCWarby ParkerNYSE:WRBYNational VisionNASDAQ:EYEEdap TmsNASDAQ:EDAPView All CompetitorsInsiders & InstitutionsCaxton Associates LPBought 23,427 shares on 5/16/2024Ownership: 0.063%Price T Rowe Associates Inc. MDBought 994 shares on 5/15/2024Ownership: 0.165%Lazard Asset Management LLCSold 280 shares on 5/15/2024Ownership: 0.017%EntryPoint Capital LLCSold 294 shares on 5/14/2024Ownership: 0.001%Seven Eight Capital LPBought 3,248 shares on 5/13/2024Ownership: 0.082%View All Insider TransactionsView All Institutional Transactions RXST Stock Analysis - Frequently Asked Questions Should I buy or sell RxSight stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RXST shares. View RXST analyst ratings or view top-rated stocks. What is RxSight's stock price target for 2024? 7 analysts have issued 1 year price objectives for RxSight's stock. Their RXST share price targets range from $32.00 to $75.00. On average, they predict the company's stock price to reach $60.63 in the next year. This suggests that the stock has a possible downside of 4.2%. View analysts price targets for RXST or view top-rated stocks among Wall Street analysts. How have RXST shares performed in 2024? RxSight's stock was trading at $40.32 at the beginning of the year. Since then, RXST shares have increased by 56.9% and is now trading at $63.27. View the best growth stocks for 2024 here. When is RxSight's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our RXST earnings forecast. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) issued its quarterly earnings results on Monday, May, 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.08. The company had revenue of $29.51 million for the quarter, compared to the consensus estimate of $27.56 million. RxSight had a negative trailing twelve-month return on equity of 27.68% and a negative net margin of 44.01%. RxSight's revenue for the quarter was up 68.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.42) EPS. What ETFs hold RxSight's stock? ETFs with the largest weight of RxSight (NASDAQ:RXST) stock in their portfolio include Counterpoint Quantitative Equity ETF (CPAI), SPDR S&P Health Care Equipment ETF (XHE), Inspire Fidelis Multi Factor ETF (FDLS), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Small Cap Growth AlphaDEX Fund (FYC) and iShares Micro-Cap ETF (IWC).First Trust Small Cap Core AlphaDEX Fund (FYX). What guidance has RxSight issued on next quarter's earnings? RxSight issued an update on its FY 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $132.0 million-$137.0 million, compared to the consensus revenue estimate of $131.6 million. When did RxSight IPO? RxSight (RXST) raised $125 million in an IPO on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's stock is owned by many different institutional and retail investors. Top institutional investors include Lord Abbett & CO. LLC (4.79%), Vanguard Group Inc. (4.12%), Allspring Global Investments Holdings LLC (0.50%), Russell Investments Group Ltd. (0.45%), M&G Plc (0.38%) and Capstone Investment Advisors LLC (0.34%). Insiders that own company stock include Bakker Juliet Tammenoms, Eric Weinberg, Ilya Goldshleger, Jesse Anderson Corley, Robert Keith Warner, Ronald M Md Kurtz, Shelley B Thunen, Shweta Maniar and William J Phd Link. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RXST) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.